MANNKIND CORP Deferred Tax Assets, Tax Deferred Expense, Other
MANNKIND CORP (MNKD) had Deferred Tax Assets, Tax Deferred Expense, Other of $7.71 million as of 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross › Deferred Tax Assets, Tax Deferred Expense
us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther · last filed 2026-02-26
- 2025-12-31: Deferred Tax Assets, Tax Deferred Expense, Other $7.71M.
- 2024-12-31: Deferred Tax Assets, Tax Deferred Expense, Other $4.97M.
- 2023-12-31: Deferred Tax Assets, Tax Deferred Expense, Other $3.40M.
- 2022-12-31: Deferred Tax Assets, Tax Deferred Expense, Other $3.20M.
| Period end | Deferred Tax Assets, Tax Deferred Expense, Other |
|---|---|
| 2025-12-31 | $7.71M 10-K · filed 2026-02-26 |
| 2024-12-31 | $4.97M 10-K · filed 2026-02-26 |
| 2023-12-31 | $3.40M 10-K · filed 2025-02-26 |
| 2022-12-31 | $3.20M 10-K · filed 2024-02-27 |
| 2021-12-31 | $2.57M 10-K · filed 2023-02-23 |
| 2020-12-31 | $2.09M 10-K · filed 2022-02-24 |
| 2019-12-31 | $147.00K 10-K · filed 2021-02-25 |
| 2018-12-31 | $669.00K 10-K · filed 2020-02-25 |
| 2017-12-31 | $795.00K 10-K · filed 2019-02-26 |
| 2016-12-31 | $7.38M 10-K · filed 2018-02-27 |
| 2015-12-31 | $7.19M 10-K · filed 2017-03-16 |
| 2014-12-31 | $131.00K 10-K · filed 2016-03-15 |
| 2013-12-31 | $837.00K 10-K · filed 2015-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |